Merck Kgaa (MKGAF)

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility program in 2026.

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Engine Capital, holding a 3% stake in Avantor, urges the board to pursue a turnaround or sale, citing years of underperformance, missed targets, and lost market share.

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to $1.5 billion in milestones plus royalties.

Merck KGaA (OTC: MKGAF) (OTC: 

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have rights to manufacture and commercialize the drug.

Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova. 

Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported 

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22, 

Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) 

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...

Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE...

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the...